Animal Gastroesophageal Reflux Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Animal Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

Global Animal Gastroesophageal Reflux Disease Market was valued at USD 3.46 Billion in 2024 and is expected to reach USD 5.44 Billion in the forecast period with a CAGR of 7.81% through 2030. The global animal gastroesophageal reflux disease (GERD) market is experiencing steady growth driven by the increasing prevalence of gastrointestinal disorders among pets. GERD, characterized by the backflow of stomach acids into the esophagus, is becoming a common concern in companion animals, particularly in dogs and cats. The rise in pet ownership and changing lifestyles, with more pets living indoors and being treated as family members, contribute to this increase. As pets are more frequently exposed to processed foods, obesity, and stress, the incidence of digestive health issues, including GERD, is rising. Pet owners' growing awareness of gastrointestinal health is encouraging them to seek timely treatments, further fueling the demand for veterinary care and specialized treatments for GERD.

Technological advancements in veterinary care play a significant role in the growth of the GERD market. Innovative diagnostic tools, such as endoscopy and esophageal pH monitoring, are improving the detection of GERD, leading to more accurate diagnoses and timely treatments. Moreover, the development of targeted therapeutic interventions, including proton pump inhibitors (PPIs), H2 blockers, and dietary management products, has made it easier to manage GERD in pets. The expansion of veterinary pharmacies and online platforms has made these treatments more accessible to pet owners worldwide. Pet owners are increasingly opting for customized care solutions, such as specialized diets and medications, further contributing to the market's expansion.

Despite its growth, the animal GERD market faces several challenges that may hinder its full potential. One of the major obstacles is the limited awareness among pet owners about the long-term implications of untreated GERD, often leading to delayed diagnoses and treatments. Furthermore, the high cost of advanced diagnostic procedures and treatments can be a barrier, particularly for pet owners in low-income regions. The lack of standardized treatment protocols across different regions also leads to variability in care quality. Veterinary clinics may also face challenges in adopting the latest diagnostic and treatment technologies due to high investment costs. Addressing these challenges while capitalizing on opportunities for innovation in diagnostics and therapies will be crucial for the market's sustained growth in the forecast period.

Key Market Drivers

Rising Prevalence of Gastrointestinal Disorders in Pets

The increasing prevalence of gastrointestinal disorders in pets is a significant driver for the global animal gastroesophageal reflux disease (GERD) market. Gastrointestinal issues, including GERD, are commonly observed in both dogs and cats, leading to discomfort and health complications. A study published in 2021 in the journal Veterinary Record highlighted that gastrointestinal disorders are among the most frequent reasons for veterinary consultations, indicating a high incidence of such conditions in pets.

The rising number of pets worldwide contributes to the increased occurrence of these disorders. According to the American Pet Products Association (APPA), as of 2021, approximately 67% of U.S. households owned a pet, equating to about 85 million families. This surge in pet ownership correlates with a higher demand for veterinary care, including treatments for gastrointestinal conditions.

The escalating prevalence of gastrointestinal disorders in pets underscores the need for effective treatments and preventive measures, thereby propelling the growth of the animal GERD market. Veterinary professionals are increasingly focusing on diagnosing and managing these conditions, leading to a higher demand for specialized medications and therapies. This trend is expected to continue as pet owners become more proactive about their pets' health, further driving market expansion.

Advancements in Veterinary Care and Diagnostic Technologies

Advancements in veterinary care and diagnostic technologies have been pivotal in driving the growth of the global animal gastroesophageal reflux disease (GERD) market. The increasing recognition of GERD in animals, especially in dogs and cats, has led to the development of more sophisticated diagnostic tools and treatment options. High-resolution imaging techniques, such as endoscopy, fluoroscopy, and esophageal pH monitoring, allow veterinarians to obtain accurate and detailed information about the esophagus and stomach. These technologies enable more precise diagnosis and monitoring of reflux events, contributing to better treatment outcomes.

Veterinary practices have also seen the integration of impedance testing, a technology that measures both acid and non-acid reflux, offering deeper insights into the nature of the disease and its progression in animals. As diagnostic capabilities improve, the early detection of GERD in animals has become more feasible, resulting in timely intervention and better management of the condition.

The humanization of pets and increased awareness among pet owners about animal health are driving the demand for advanced treatments and medical technologies. More pet owners are willing to invest in their animals' health, which further fuels the growth of the market.

These factors, combined with the continuous innovation in veterinary medical equipment and therapies, including proton pump inhibitors and surgical techniques, have significantly contributed to the expansion of the animal GERD market. The advancements not only offer better disease management but also improve the quality of life for animals suffering from this chronic condition. With technological progress continuing to evolve, the market is expected to see sustained growth, driven by the need for improved diagnostics and effective treatment solutions for animal GERD.

Availability of Specialized GERD Treatments

The availability of specialized GERD treatments has been a significant driver in the global animal gastroesophageal reflux disease (GERD) market. The development of advanced pharmacological treatments and surgical interventions has greatly enhanced the management of GERD in animals, particularly in pets such as dogs and cats. In recent years, the introduction of proton pump inhibitors (PPIs) and H2-receptor antagonists for animals has revolutionized the way GERD is treated, offering targeted relief from acid reflux and improving esophageal health. These medications not only reduce gastric acid production but also support mucosal healing in the esophagus, providing long-term benefits for affected animals.

Surgical procedures, such as fundoplication, have also gained prominence in the veterinary field. These techniques, designed to prevent the backflow of stomach contents into the esophagus, are increasingly being performed in veterinary clinics specializing in gastrointestinal diseases. The success rates of these surgeries have contributed to greater confidence in their application, driving demand for specialized GERD treatments.

Veterinary professionals' growing awareness and education on GERD in animals have further fueled the availability of specialized treatments. In many regions, veterinary practices have become better equipped to diagnose and treat GERD, leading to earlier intervention and improved treatment outcomes. This availability of specialized care has made GERD treatment more accessible, encouraging pet owners to seek timely medical assistance for their pets.

As a result of these advancements, the global animal GERD market has seen steady growth, driven by the increasing availability and adoption of specialized GERD treatments, ensuring better health and well-being for animals affected by this condition.

Key Market Challenges

Underdiagnosis and Misdiagnosis

Underdiagnosis and misdiagnosis represent significant challenges in the global animal gastroesophageal reflux disease (GERD) market. GERD symptoms in animals, such as vomiting, difficulty swallowing, or regurgitation, often overlap with those of other gastrointestinal conditions, leading to difficulty in distinguishing GERD from other disorders. The lack of clear and specific symptoms, especially in non-human animals, often causes veterinarians to overlook or misinterpret the underlying condition. Without accurate identification, GERD remains undiagnosed, which delays proper treatment and exacerbates the disease's progression.

In many cases, veterinary professionals rely on limited diagnostic tools such as physical examinations, which may not provide sufficient information about the esophagus or stomach's condition. Despite advancements in veterinary diagnostics, such as endoscopy, pH monitoring, and impedance testing, these technologies are not universally available in all veterinary clinics, especially in developing regions. This technological gap increases the risk of underdiagnosis and misdiagnosis, as well as delays in providing effective treatment for affected animals.

The financial cost of comprehensive diagnostic procedures also plays a role in underdiagnosis. Not all pet owners are willing or able to invest in expensive diagnostic tests, leading to conservative treatment approaches that may fail to address the underlying GERD. Misdiagnosis often results in inappropriate treatments that do not resolve the condition, further complicating the situation for both veterinarians and pet owners.

As the awareness of GERD in animals grows, addressing these diagnostic challenges will become crucial for improving care and treatment outcomes. However, the presence of these challenges continues to hinder market growth, as they delay accurate diagnosis and appropriate therapeutic interventions, ultimately affecting animal health outcomes.

Lack of Standardized Treatment Protocols

One of the key challenges in the global animal gastroesophageal reflux disease (GERD) market is the lack of standardized treatment protocols. Unlike human healthcare, where treatment guidelines for GERD are well established, veterinary medicine struggles to maintain consistent and widely accepted practices for diagnosing and managing GERD in animals. This inconsistency results in varied approaches across regions and veterinary practices, leading to suboptimal patient outcomes.

Veterinarians often rely on a combination of clinical symptoms, endoscopy, and diagnostic imaging to diagnose GERD in animals. However, without a universal treatment protocol, the approaches to medication, diet, and surgical interventions differ, depending on the veterinarian's experience, regional practices, and available resources. This leads to challenges in determining the most effective therapy for each case, and it can result in delayed or inadequate treatment, impacting the health and quality of life of the affected animals.

The lack of standardized treatment also hinders the development of innovative therapies tailored specifically for veterinary use. As the field of veterinary gastroenterology is relatively underdeveloped compared to human medicine, pharmaceutical companies and researchers may be reluctant to invest in research to create specialized treatments for animals, such as more effective proton pump inhibitors or anti-reflux agents. Consequently, animal owners may have limited access to effective, evidence-based treatments for GERD, and practitioners may face challenges in managing chronic cases.

The absence of universal guidelines and treatment protocols also impacts the global market for animal GERD. Veterinary practices face obstacles in providing consistent care, and pet owners struggle to make informed decisions regarding their pets' treatment options. This gap in standardized care ultimately slows down market growth, as it inhibits the establishment of a uniform framework for treating GERD across the veterinary field.

Key Market Trends

Increasing Availability of Specialized Therapeutic Diets

The global animal gastroesophageal reflux disease (GERD) market is experiencing a notable trend driven by the increasing availability of specialized therapeutic diets. As pet owners become more aware of the role that diet plays in managing gastrointestinal disorders, including GERD, there has been a surge in the demand for veterinary-specific food products. These diets are formulated to reduce acid reflux symptoms, improve digestion, and promote overall gastrointestinal health in animals.

Veterinary food manufacturers are focusing on creating highly digestible, low-fat, and pH-balanced food options that can help manage the symptoms of GERD in animals. Many of these specialized diets are enriched with ingredients like prebiotics, probiotics, and antioxidants, which support digestive health while ensuring that the pet's nutritional needs are met. Additionally, these diets often include highly palatable options that are designed to encourage pet owners to follow dietary recommendations more closely.

Veterinary professionals are increasingly recommending therapeutic diets as part of comprehensive treatment plans for animals diagnosed with GERD. These diets help manage the condition effectively by providing relief from symptoms such as regurgitation and discomfort, which are common in animals with this condition. The growing availability of such diets reflects the broader trend of humanization of pets, where owners are willing to invest in specialized healthcare products to improve the quality of life for their animals.

The focus on diet-based management also aligns with advancements in veterinary care, where holistic approaches to animal health are prioritized. As a result, the availability of therapeutic diets is expected to continue growing, enhancing the effectiveness of GERD treatments and providing relief to pets suffering from gastrointestinal issues.

Collaborations Between Veterinary Pharma Companies and Research Institutions

Collaborations between veterinary pharmaceutical companies and research institutions have become a significant trend in advancing the global animal gastroesophageal reflux disease (GERD) market. These partnerships aim to enhance the understanding of GERD in animals and develop effective diagnostic and therapeutic solutions.

A notable example is the collaboration between Nestle Purina PetCare and the Gastrointestinal Laboratory at Texas A&M University's School of Veterinary Medicine & Biomedical Sciences. In April 2023, they established a five-year partnership, supported by a USD 2 million Purina PetCare Research Excellence Fund, to advance pet microbiome health. This initiative focuses on developing new diagnostic and nutritional tools to improve gastrointestinal health in pets, which is closely related to conditions like GERD.

Similarly, TriviumVet, a veterinary research and development company, has been actively involved in publishing research on gastric acid suppression in dogs. In March 2024, they announced the publication of a clinical study assessing their first product in development, a gastric acid suppressant aimed at treating gastric ulceration in dogs. This research addresses an unmet need in veterinary medicine, as there are currently no veterinary-approved pharmaceutical treatments for gastric ulceration in dogs.

These collaborations are crucial for bridging the gap between veterinary practice and scientific research, leading to the development of targeted treatments and diagnostic tools for GERD in animals. By combining the expertise of pharmaceutical companies with the research capabilities of academic institutions, these partnerships drive innovation and improve the quality of veterinary care.

Segmental Insights

Animal Type Insights

Based on the Animal Type, Companion Animals emerged as the dominant segment in the Global Animal Gastroesophageal Reflux Disease Market in 2024. This is driven by the increasing humanization of pets, with more pet owners treating their animals as family members and prioritizing their health and well-being. The rising awareness of gastrointestinal disorders in companion animals has prompted owners to seek out advanced veterinary care for conditions like GERD, leading to an uptick in demand for both diagnostic and therapeutic options. Companion animals, particularly those with predisposing factors such as obesity, age, and diet, are more susceptible to gastrointestinal issues, including GERD. These factors have contributed to a growing number of diagnosed cases. Furthermore, advancements in veterinary diagnostics, including high-resolution endoscopy and non-invasive tests, have made it easier to detect GERD in companion animals. Pet owners are increasingly willing to invest in specialized treatments, such as proton pump inhibitors and other gastric acid suppressors, further driving market growth. The high spending on pet healthcare, alongside a strong bond between pets and owners, ensures that the companion animal segment remains a dominant force in the global animal GERD market.

Route of Administration Insights

Based on the Route of Administration, Oral emerged as the dominant segment in the Global Animal Gastroesophageal Reflux Disease Market in 2024. This is due to its convenience, effectiveness, and ease of use for both veterinarians and pet owners. Oral medications, such as proton pump inhibitors and histamine-2 receptor antagonists, are widely preferred for treating GERD in animals, particularly companion animals like dogs and cats. These medications are available in various forms, including tablets, capsules, and liquid solutions, making it easier for pet owners to administer them at home without the need for veterinary visits. The convenience of oral administration is a key driver of its dominance. Pet owners can easily follow prescribed dosing schedules without the stress of administering injections or other more invasive treatments. Oral medications for GERD are also effective in managing symptoms such as acid reflux, regurgitation, and discomfort, providing long-term relief for animals. Additionally, oral drugs often have a lower cost compared to injectable alternatives, making them more accessible to a larger number of pet owners.

Regional Insights

North America emerged as the dominant region in the Global Animal Gastroesophageal Reflux Disease Market in 2024. This is due to several factors, including advanced veterinary care, high pet ownership rates, and increasing awareness of animal health. The region, particularly the United States, has a strong veterinary healthcare infrastructure, with access to state-of-the-art diagnostic tools and treatments for gastrointestinal disorders in animals. Veterinarians in North America are well-equipped to diagnose and manage conditions like GERD, contributing to higher detection rates and subsequent treatment of affected animals. The growing trend of pet humanization in North America, where pets are increasingly considered family members, has led to a rise in healthcare spending on animals. Pet owners are more willing to seek specialized care and invest in treatments for their pets, driving the demand for veterinary medications, including those used to manage GERD. Furthermore, the region benefits from well-established pharmaceutical companies that develop and distribute GERD treatments for animals, ensuring the availability of effective therapeutic options. In addition, the prevalence of risk factors such as obesity, aging populations of pets, and high-stress environments in North American households contribute to the growing number of GERD cases in companion animals, making the region a key market for animal GERD treatments.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale S.A.
• Boehringer Ingelheim International GmbH
• McNeil Consumer Pharmaceuticals Co.
• BioZyme, Inc.
• Annamaet Petfoods Inc.
• Hill's Pet Nutrition, Inc.
• Blue Buffalo Co., Ltd.

Report Scope:

In this report, the Global Animal Gastroesophageal Reflux Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Gastroesophageal Reflux Disease Market, By Product:

• Diagnostics
• Treatment
• Others

Animal Gastroesophageal Reflux Disease Market, By Animal Type:

• Companion Animals
• Livestock Animals

Animal Gastroesophageal Reflux Disease Market, By Route of Administration:

• Oral
• Injectable

Animal Gastroesophageal Reflux Disease Market, By Distribution Channel:

• Veterinary hospitals & clinics
• Retail Pharmacies
• E-commerce

Animal Gastroesophageal Reflux Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Gastroesophageal Reflux Disease Market.

Available Customizations:

Global Animal Gastroesophageal Reflux Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).